GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » ROE % Adjusted to Book Value

Pluri (PLUR) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Pluri ROE % Adjusted to Book Value?

Pluri's ROE % for the quarter that ended in Mar. 2024 was -1,047.34%. Pluri's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Pluri's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.

Pluri ROE % Adjusted to Book Value Historical Data

The historical data trend for Pluri's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri ROE % Adjusted to Book Value Chart

Pluri Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -32.71 -18.61 -39.85 -71.13 -52.63

Pluri Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -65.61 -64.27 -63.91 -53.74 -

Competitive Comparison of Pluri's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Pluri's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pluri's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pluri's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pluri's ROE % Adjusted to Book Value falls into.


Pluri ROE % Adjusted to Book Value Calculation

Pluri's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-130.53% / 2.48
=-52.63%

Pluri's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1,047.34% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pluri ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Pluri's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Pluri (PLUR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
IGXT ABIO RNXT VTVT AURX LUMO VINC EQ ELEV OCEA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
Y55:Germany
Address
MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409
Website
https://www.pluri-biotech.com
Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.
Executives
Lorne Kenneth Abony director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman officer: Chief Executive Officer 63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership 10 percent owner BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen director MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer director 33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun director 9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay officer: Chief Financial Officer ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat director HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram director 24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda officer: Chief Financial Officer MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain director WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi officer: Chief Financial Officer MATAM PARK, BUILDING 05, HAIFA L3 31905